Loading...
Market
New types of disorders targeted by CRISPR by end of 2024
5
Resolution / Starting Odds
Neurological disorders • 25%
Muscular disorders • 25%
Metabolic disorders • 25%
No new types • 25%
New clinical trial announcements or major biotech industry reports
Story
Kendric Cromer Receives First Sickle Cell Gene Therapy; CRISPR Shows Safety, Efficacy in Blindness
May 6, 2024, 02:00 PM
Recent advancements in gene therapy have shown significant progress in treating various inherited diseases. Kendric Cromer, a 12-year-old boy from the Washington, D.C. area, has become the first person to receive a newly approved gene therapy for sickle cell disease, expressing his desire to be cured. Clinical trials have demonstrated the efficacy of CRISPR gene editing in treating inherited forms of blindness, with improvements in vision for several patients and showing safety and early evidence of efficacy. Additionally, gene therapies are also being developed for other conditions, such as skeletal defects and inherited retinal diseases, showing early signs of effectiveness and safety.
View original story
Similar markets
Cancer • 20%
Rare genetic disorders • 20%
Heart disease • 20%
Neurological disorders • 20%
Other • 20%
Liver Disease • 25%
Cystic Fibrosis • 25%
Muscular Dystrophy • 25%
Hemophilia • 25%
Cancer • 25%
Alzheimer's Disease • 25%
Cystic Fibrosis • 25%
Sickle Cell Disease • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
More than 20 • 25%
Transthyretin Amyloidosis • 25%
Sickle Cell Disease • 25%
Cystic Fibrosis • 25%
Muscular Dystrophy • 25%
Cancer • 25%
Rare Genetic Disorders • 25%
Heart Disease • 25%
Neurodegenerative Diseases • 25%
Cardiovascular diseases • 25%
Neurodegenerative diseases • 25%
Cancer • 25%
Rare genetic disorders • 25%
None • 25%
1-2 new conditions • 25%
3-4 new conditions • 25%
5 or more new conditions • 25%
1-2 genes • 33%
3-5 genes • 33%
6 or more genes • 33%
No new approvals • 25%
1 new approval • 25%
2 new approvals • 25%
3 or more new approvals • 25%
1-2 diseases • 33%
3-4 diseases • 33%
5 or more diseases • 33%